Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Revenues
Product revenue, net	$ 13,482,282	$ 8,156,173	$ 42,149,561	$ 12,771,235
Operating expenses
Cost of sales	13,682,297	1,998,659	23,499,842	2,980,425
Research and development	389,262	78,502	858,698	223,197
Selling, general and administrative	12,851,087	9,190,386	35,825,175	19,494,368
Acquisition related costs	1,536,800	311,083	2,849,037	1,533,723
Restructuring costs	4,818,064		4,874,723	135,981
Amortization and impairment of intangible assets	5,870,436	1,370,986	9,039,597	2,899,553
Total operating expenses	39,147,946	12,949,616	76,947,072	27,267,247
Loss from operations	(25,665,664)	(4,793,443)	(34,797,511)	(14,496,012)
Other (expense) income
Other (expense), net	(425,425)	(538,862)	(1,555,924)	(1,181,206)
Gain / (Loss) from change in fair value of contingent consideration	631,298		(2,680,022)
Gain from derecognition of contingent consideration				5,199,806
Gain from warrant derivative liability				1,830
Loss on debt exchange			(257,559)
Total other (expense) income	205,873	(538,862)	(4,493,505)	4,020,430
Net loss	$ (25,459,791)	$ (5,332,305)	$ (39,291,016)	$ (10,475,582)
Weighted average number of common shares outstanding (in shares)	18,092,465	3,527,530	14,490,219	2,261,697
Basic and diluted net loss per common share (in dollars per share)	$ (1.41)	$ (1.51)	$ (2.71)	$ (4.63)